1. Introduction {#s0035}
===============

Hepatitis C virus (HCV) therapy is living a revolution, with four already approved new antiviral agents and dozens at Phase 2 or 3 clinical developmental stages. New HCV drugs split into two groups: direct-acting antivirals (DAAs), that target viral actors of the HCV lifecycle, and host-targeted agents (HTAs), that block HCV production by interacting with host cell components ([@b0095]). For many years, only HTAs were available for the treatment of chronic hepatitis C. They included interferon-α (IFN-α), which triggers an intracellular cascade of events that, in turn, activate a number of nonspecific antiviral cellular effectors, and ribavirin, a drug that accelerates infected cell clearance or cure when HCV production is potently inhibited through yet unknown mechanisms ([@b0010], [@b0125], [@b0020], [@b0050]). More recently, HTAs targeting host cell components involved in complex interactions with viral proteins that are essential to the HCV lifecycle have been developed.

2. The hepatitis C virus lifecycle {#s0005}
==================================

The HCV lifecycle starts with receptor binding at the surface of hepatocytes. HCV entry into cells is pH-dependent and related to clathrin-mediated endocytosis. It is followed by a fusion step within an acidic endosomal compartment. Decapsidation of viral nucleocapsids liberates free positive-strand genomic RNAs in the cell cytoplasm, where they serve, together with newly synthesized RNAs, as messenger RNAs for synthesis of the HCV polyprotein. The polyprotein is targeted to the endoplasmic reticulum membrane where co- and post-translational processing by host cell peptidases, the NS2 autocatalytic protease and the NS3-4A serine protease results in the generation of the 3 structural proteins (C or core, E1 and E2), the p7 viroporin, and the 6 nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B). Replication is catalyzed by the HCV RNA-dependent RNA polymerase (RdRp) or NS5B protein. The NS5A protein and the NS3 helicase-NTPase domain of the NS3 protein play an important regulatory role in virus replication, whereas NS4B serves as a membrane anchor for the replication complex and plays an important role in membrane rearrangements leading to its formation. Viral particle formation is initiated by the interaction of the core protein with genomic RNA. HCV then uses the lipoprotein production pathway to generate mature viral particles and export them ([@b0065], [@b0070], [@b0075], [@b0135]) .

3. Host factors involved in the HCV lifecyle {#s0010}
============================================

Host cell proteins are involved at every step of the HCV lifecycle (see [Table 1](#t0005){ref-type="table"} ). HCV entry is mediated by several cell surface and tight junction proteins, including the low-density lipoprotein (LDL) receptor, CD81, the scavenger receptor B1, claudin-1, occludin and the epidermal growth factor receptor ([@b0135]).Table 1Host factors that are known to be involved in the hepatitis C virus lifecycle.Hepatitis C virus lifecycle stepHost factors known to be involvedEntry into cellsLDL receptorCD81 moleculeScavenger receptor B1Claudin-1OccludinEpidermal growth factor receptorViral polyprotein translationCellular ribosomal machineryeIF2, eIF3 and eIF5La proteinNSAP1hnRNP L and DIMP-1Gemin 5"like Sm" protein LSm1-7PCBP2miR-122NFARViral genome replicationHost cell lipids and lipid dropletsPI4KIIIαFBL2Cyclophilin AmiR-122hVAP-A and hVAP-Bcellular RNA-binding proteinsVirion assembly and releaseApolipoproteins B and EMTPESCRTRecycling endosomal compartmentsPhospholipase A2μ1 subunit of AP2M1Annexin 2Stress granule proteinsVAMP

Translation uses the cellular ribosomal machinery and three eukaryotic initiation factors (eIF): eIF2, eIF3 and eIF5. It also recruits noncanonical RNA-binding proteins, including the La protein, NSAP1 (NS1-associated protein 1), hnRNP (heterogeneous nuclear ribonucleoproteins) L and D, IMP-1 (insulin-like growth factor 2 mRNA binding protein 1), gemin-5, "like-Sm" protein LSm1-7, and PCBP2 (poly(rC) binding protein 2), which interact with the viral genome and with each other ([@b0075]). MicroRNA-122 (miR-122) fixation to the 5′ noncoding region of the genome appears to stimulate translation by stabilizing the RNA. The contribution of the 3′ end of the viral genome to translation appears to be mediated by two cell proteins, the NFAR (nuclear factors associated with dsRNA) protein complex and IMP-1 ([@b0075]).

A number of host cell proteins have been shown to contribute to the formation of the replication complex (or membranous web), such as PI4KIIIα (lipid kinase phosphatidylinositol 4-kinase III alpha), FBL2 (F-box and leucine rich repeat protein 2), host cell lipids and lipid droplets ([@b0070]). A large number of viral proteins are involved in RNA synthesis, which is catalyzed by the viral RdRp under the control of the viral NS5A protein. They have been shown to interact with both viral proteins and to be required for viral replication. They include cyclophilin A, miR-122, hVAP-A (human VAMP-associated protein A) and its isoform hVAP-B, and cellular RNA-binding proteins ([@b0070]).

HCV particle assembly shares numerous features with the VLDL/LDL assembly pathway, interacting with a number of apolipoproteins, in particular apoB and apoE, while MTP (microsomal triglyceride transfer protein) plays a major role in VLDL secretion and viral particle production ([@b0065]). In addition, HCV uses the ESCRT (endosomal-sorting complex required for transport) pathway, recycling endosomal compartments and a number of host cell factors (e.g. phospholipase A2, the μ1 subunit of AP2M1 \[clathrin adapter protein complex 2\], annexin A2, and stress granule proteins) for assembly and budding from the cytoplasm. Viral particles then pass through the Golgi apparatus in a VAMP-dependent manner ([@b0065]).

4. Host-targeted approaches {#s0015}
===========================

Blocking the interaction of any of these cell components with the HCV lifecycle results in an efficient blockade of viral production, as shown *in vitro* with specific inhibitors or silencing RNAs. Thus, numerous host-targeted approaches can theoretically be envisaged to inhibit HCV replication. However, only two reached clinical development thus far, including specific inhibitors of cyclophilin A peptidyl-prolyl *cis/trans* isomerase activity and antagonists of miR-122. Both classes of compounds reduced viral replication by several logs when administered to infected patients in Phase Ib and II clinical trials ([@b0025], [@b0045]). Drugs that interact with the lipid metabolism, such as statins, have been shown to inhibit the *in vitro* replication of HCV by blocking the late steps of the HCV lifecycle. The potential clinical benefit of statins in HCV-infected patients is at best modest ([@b0080], [@b0090], [@b0140]). Given the results of current and future anti-HCV therapies, it is unlikely that other host-targeted approaches will reach clinical development in this indication.

5. The place of host-targeted agents in HCV therapy {#s0020}
===================================================

The vast majority of new HCV drugs in development are DAAs. They include inhibitors of the NS3-4A protease, nucleoside/nucleotide analogue inhibitors of the HCV RdRp, non-nucleoside inhibitors of RdRp, and NS5A inhibitors ([@b0095]). These compounds are potent. Most first-generation drugs have a low barrier to resistance, with the notable exception of nucleoside/nucleotide analogues. Second-generation drugs with a higher barrier to resistance are currently being developed ([@b0095]). What is, in this context, the place of host-targeted agents?

To cure HCV infection, a drug regimen must combine antiviral potency and a high barrier to resistance that ensures that inhibition of virus production is sustained over the full treatment period. When this is the case, infected cells progressively eliminate the RNA genomes they contain until no more cells are infected at the time treatment is withdrawn. Cyclophilin A inhibitors were shown to potently inhibit viral replication, both *in vitro* and *in vivo* ([@b0025], [@b0085]). Because they target conserved host proteins, not variable viral proteins, both cyclophilin A inhibitors and miR-122 antagonists have pangenotypic antiviral activity and a high barrier to resistance ([@b0015], [@b0025], [@b0055], [@b0085], [@b0115]). No resistance has been reported thus far with miR-122 antagonists *in vivo*. However, viral polymorphisms associated with resistance to miR-122 antagonism have been reported in a recent *in vitro* study ([@b0060]). Whether such variants naturally exist in infected patients is unknown. Amino acid substitutions in viral proteins are hardly selected by cyclophilin A inhibitors after numerous passages *in vitro* ([@b0015], [@b0025], [@b0055], [@b0085], [@b0115]). They are essentially located in the NS5A protein sequence, confer minor reduction in drug susceptibility *in vitro*, and do not appear to play a role in cyclophilin inhibitor treatment failures *in vivo*. HTAs thus represent ideal "backbones" for pangenotypic drug combinations with potent antiviral activity and a high barrier to resistance, both for first-line use in treatment-naïve patients or rescue therapy in patients who failed on prior IFN-containing or IFN-free regimens.

Host-targeted anti-HCV approaches however have caveats. In theory, because they target host cellular functions that may be essential to cell survival, they can be toxic. The peptidyl-prolyl *cis/trans* isomerase activity of cyclophilins catalyzes the isomerization of peptide bonds at proline residues and facilitates protein folding. However, mice knocked-out for cyclophilins are viable, and they even seem to be protected against lethal heart ischemia--reperfusion injury ([@b0005]). In clinical practice, the administration of alisporivir, a cyclophilin A inhibitor derived from cyclosporine A currently in Phase II clinical development, was associated with mild to moderate hyperbilirubinemia, that was dose-dependent and reversible upon treatment withdrawal. Hyperbilirubinemia was mixed, due to inhibition of the uptake unconjugated bilirubin transporters organic anion transporter bilirubin OATP1B1 and OATP1B3 and of conjugated bilirubin efflux transporter canalicular multispecific organic anion transporter 1 MRP2, without inhibition of glucuronide conjugation ([@b0025], [@b0105]). Alisporivir administration was also associated with hypertriglyceridemia ([@b0105]), which may have aggravated acute pancreatitis cases that occurred in combination with IFN-α (including one fatal case). For this reason, the clinical efficacy of alisporivir is currently being studied as part of IFN-free combinations only. No side effects were observed over 2 weeks of administration of miravirsen, an miR-122 antagonist ([@b0045]). However, concerns have been raised as to the long-term effects of inhibiting miR-122, because low miR-122 levels in hepatocytes have been reported to be associated with hepatocellular carcinoma ([@b0130]).

Theoretically, any approach targeting host cell functions involved in the HCV lifecycle can lead to expected or unexpected side effects. It must be noted, however, that unexpected, sometimes serious adverse events are not specific for HTAs. Numerous side effects have been reported with inhibitors from each of the different classes of HCV DAAs. The development of several compounds was halted early because of serious adverse events, including fatal cases. The large-scale use of the two first-generation protease inhibitors telaprevir and boceprevir in combination with pegylated IFN-α and ribavirin was associated with frequent side effects, with particular toxicity in patients with advanced liver disease ([@b0040]). Finally, not all DAAs currently in clinical development are entirely safe. Overall, over the past 10 years of HCV drug development, HTAs directly targeting host cell components involved in the HCV lifecycle did not appear to be substantially more toxic than DAAs.

The high barrier to resistance of HTAs means that, in contrast with DAAs, their antiviral effect is not or poorly influenced by viral genetic polymorphisms. However, HTAs are exposed to host genetic polymorphisms that may alter their ability to block their target protein function. In clinical practice, 10 to 15% of patients have a suboptimal antiviral response to alisporivir ([@b0100]). The underlying mechanism is unknown. More work is needed to understand the genetic basis of primary non-response to host-targeted approaches.

Drug-drug interactions are possible with HTAs, like with DAAs, depending on the metabolic pathways they use. Their mode of administration can also be an issue. Cyclophilin inhibitors are administered orally, but the miR-122 antagonist miravirsen must be injected, a clear disadvantage at the era of all-oral therapies ([@b0045]). Future host-targeted approaches will need to be orally administered.

Where will host-targeted approaches fit in the HCV drug armamentarium? Currently, the only viable approach seems to be cyclophilin inhibition. Indeed, cyclophilin inhibitors can be confidently used as backbones of all-oral, IFN-free regimens because of their potency, their pangenotypic activity, their high barrier to resistance and their good tolerance in the absence of IFN-α co-administration. A recent study showed that alisporivir has synergistic effects *in vitro* with different families of DAAs ([@b0035]). Thus, drug regimens combining a cyclophilin inhibitor with a protease inhibitor, an RdRp inhibitor and/or an NS5A inhibitor with or without ribavirin are credible and will likely enter clinical evaluation soon. Whether or not other host-targeted approaches should be investigated for the treatment of HCV infections is debatable. In this respect, it is interesting to note that the drug industry currently disinvests from new HCV drug screening and optimization, with the belief that enough drugs will be on the market soon to fulfill the clinical needs.

6. The place of host-targeted agents in therapy of other viral infections {#s0025}
=========================================================================

HTAs, because they target host factors involved in the viral lifecycle and not the virus itself, have the potential for broader indications than DAAs which, by nature, are active against HCV only. Cyclophilin inhibitors were shown to inhibit the replication of hepatitis B virus, HIV and coronaviruses ([@b0030], [@b0110], [@b0120]). Host-targeted antiviral approaches offer the opportunity of "panviral" antiviral approaches when they target mechanisms that are common to viruses that belong to the same or different families. Given the number of viral infections that represent important public health problems for which no specific antiviral compounds exist or are likely to be developed in the short- to mid-term, research on host-targeted approaches to combat viral infections should be encouraged. What we learnt from 20 years of HCV research and drug development may be particularly useful in this respect, making HCV an invaluable model for future antiviral drug development.
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